St Jude Medical Inc

St. Jude Medical Inc. is facing a federal securities class-action lawsuit claiming that the medical device maker and two of its top executives misrepresented the company's financial situation to shareholders last year. The lawsuit is filed in U.S. District Court in Minnesota on behalf of the City of Taylor Police and Fire Retirement System in Taylor, Mich., and others who bought St. Jude stock between April 22 and Oct. 6, 2009. It lists Little Canada-based St. Jude (NYSE:STJ), Daniel Starks, its CEO, an  

We recently reiterated our 'Neutral' recommendation for Medtronic, Inc . ( MDT - Analyst Report ) with a target price of $47 based on a P/E of roughly 13.4x our fiscal 2011 EPS estimate of $3.52. Medtronic reported third quarter fiscal 2010 earnings per share of 77 cents, surpassing the Zacks Consensus Estimate of 76 cents and the year-ago earnings of 71 cents. Total revenues in the third quarter increased 10% year over year to $3.851 billion. Medtronic witnessed sales growth across all its seven busi  

 

We maintain our Neutral recommendation for St. Jude Medical, Inc. (NYSE:STJ) with a target price of $41 based on a P/E of 14.9x our fiscal 2010 EPS estimate of $2.75. The earnings estimate revisions for this Zacks Rank #3 stock have been mixed in the past 30 days. During the past 30 days, three out of 29 analysts have upgraded their earnings estimates while two have downgraded their estimates for fiscal 2010. For fiscal 2011, three out of 25 analysts have upgraded their earnings estimates while two have  

Shares of Boston Scientific nosedived on Monday after the company announced that it has stopped shipment of two of its medical devices after determining that manufacturing process changes have not yet been approved by the Food and Drug Administration. On news of the halted shipments, shares of the medical device maker fell 12.7%, or 99 cents, to $6.79 in Monday morning trading. The two devices that the Natick, Mass.-based company have temporarily shelved are its implantable cardioverter defibrillators  

St. Jude Medical, Inc. (NYSE: STJ), a global medical device company, announced several updates to its PressureWire(TM) platform, including a new marketing agreement with Siemens Medical Solutions USA, for the wireless PressureWire(TM) Aeris and the availability of the next-generation of PressureWire(TM) Certus technology, at the American College of Cardiology (ACC) and the Society of Interventional Radiology (SIR) annual meetings. The enhanced capabilities make the company's leading Fractional Flow Reserve

The PressureWire segment is one of the biggest areas of growth for St. Jude Medical's interventional business because of its clinical benefits and ability to reduce the cost of PCI procedures   -Frank Callaghan

 

The locust question, posed by BMO Capital Markets analyst Joanne Wuensch in a research note released on Tuesday morning, should serve as the rhetorical highpoint in the capital markets frustration with the medical technology sector's one-time (and seemingly more distant every day) comeback story. "We thought BSX was testing a bottom, but we were wrong.... While our turnaround keeps getting extended, we wonder what else can go wrong, locusts?" the BMO analyst wondered. The good news, given the slim odd  

Boston Scientific drew a critical eye from Goldman Sachs Tuesday, as the medical device maker was placed on the firm's conviction sell list. The company officially recalled its implantable cardiac defibrillator devices yesterday, citing manufacturing changes that had not been approved by the Food and Drug Administration. The stock was formerly rated neutral by Goldman, and the broker says the recalled products - which amount to about a fifth of BSX profits - could hurt the device maker's reputation in  

Options investors are going hog-wild for HOG-calls this morning on speculation that motorcycle-maker, Harley-Davidson, could be the purchase target in a leveraged buyout offer by a private equity firm. Shares are up 5.45% to $27.95 on the LBO rumors, and the overall reading of options implied volatility on the stock is also 15.1% higher to 43.58%. Bullish players purchased 2,700 now in-the-money calls at the March $27 strike for a premium of $0.57 apiece, while the higher March $28 strike attracted buying  

Goldman Sachs has put Boston Scientific (BSX) on its conviction sell list today. The company officially recalled its implantable cardiac defibrillator devices yesterday, citing manufacturing changes that had not been approved by the Food and Drug Administration. The stock was formerly rated neutral by Goldman, and the broker says the recalled products which amount to about a fifth of BSX profits could hurt the device makers reputation in additional to its bottom line.